Total and serotype-specific pneumococcal antibody titres in children with normal and abnormal humoral immunity

Vaccine

Volumn 24, Issue 27-28, 2006, Pages 5637-5644

  Uddin, Sharif ^a   Borrow, Ray ^b   Haeney, Mansel R ^c   Moran, Andrew ^c   Warrington, Rosalind ^b   Balmer, Paul ^b   Arkwright, Peter D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

Children; Pneumococcal antibodies; Serotypes; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTECTION; RECURRENT INFECTION; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; AGE FACTORS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 33746793208     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.088     Document Type: Article

References (24)

1. Williams B.G., Gouws E., Boschi-Pinto C., Bryce J., and Dye C. Estimates of world-wide distributions of child deaths from acute respiratory infections. Lancet Infect Dis 2 (2002) 25-32
2. Fedson D.S., and Scott J.A. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17 Suppl. 1 (1999) S11-S18
3. Picard C., Puel A., Bustamante J., Ku C.L., and Casanova J.L. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 3 (2003) 451-459
4. Bogaert D., Hermans P.W., Adrian P.V., Rümke H.C., and de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 22 (2004) 2209-2220
5. Salyers A.A., and Whitt D.D. Streptococcus pneumoniae. Bacterial Pathogenesis: A Molecular Approach. 2nd ed. (2002), ASM Press, Washington 279-290
6. Casal J., and Tarrago D. Immunity to Streptococcus pneumoniae: factors affecting production and efficacy. Curr Opin Infect Dis 16 (2003) 219-224
7. Hausdorff W.P., Feikin D.R., and Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 5 (2005) 83-93
8. Barrett D.J., and Ayoub E.M. IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 63 (1986) 127-134
9. Schauer U., Stemberg F., Rieger C.H., Buttner W., Borte M., Schubert S., et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin Diagn Lab Immunol 10 (2003) 202-207
10. Borrow R., and Balmer P. Assessment of functional antibody responses. Method Mol Med 87 (2003) 289-300
11. Black S., Shinefield H., Baxter R., Austrian R., Bracken L., Hansen J., et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 23 (2004) 485-489
12. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 49 (2000) 1-35
13. Finn A., Booy R., Moxon R., Sharland M., and Heath P. Should the new pneumococcal vaccine be used in high-risk children?. Arch Dis Child 87 (2002) 18-21
14. Hazlewood M., Nusrat R., Kumararatne D.S., Goodall M., Raykundalia C., Wang D.G., et al. The acquisition of anti-pneumococcal capsular polysaccharide, Haemophilus influenzae type B and tetanus toxoid antibodies with age in the UK. Clin Exp Immunol 93 (1993) 157-164
15. Lal G., Balmer P., Stanford E., Martin S., Warrington R., and Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 296 (2005) 135-147
16. Jódar L., Butler J., Carlone G., Dagan R., Goldblatt D., Käyhty H., et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations of the use in infants. Vaccine 1 (2003) 3265-3272
17. International Union of Immunological Societies. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol (1999) 118-128
18. Conley M.E., Notorangelo L.D., and Etzioni A. Diagnostic criteria for primary immunodeficiencies. Clin Immunol 93 (1999) 190-197
19. Obukhanych T.V., and Nussenzweig M.C. T-independent type II immune responses generate memory B cells. J Exp Med 203 (2006) 305-310
20. Kaniuk A.S., Lortan J.E., and Monteil M.A. Specific IgG subclass antibody levels and phagocytosis of serotype 14 pneumococcus following immunisation. Scand J Immunol 11 (1992) 96-98
21. Anttila M., Voutilainen M., Jäntti V., Eskola J., and Käyhty H. Contribution of serotype-specific IgG concentrations, IgG subclass and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol 118 (1999) 402-407
22. Wuorimaa T., Dagan R., Vakevainen M., Bailleux F., Haikala R., Yaich M., et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 184 (2001) 1211-1215
23. Lucero M.G., Puulmalainen T., Ugpo J.M., Williams G., Kayhty H., and Nohynek H. Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial. J Infect Dis 189 (2004) 2077-2084
24. Southern J., Deane S., Ashton L., Borrow R., Goldblatt D., Andrews N., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 11 (2004) 1100-1104